Skip to main content
Clinical Trials/CTRI/2024/12/077668
CTRI/2024/12/077668
Not yet recruiting
Not Applicable

EFFECTIVENESS OF IMMERSIVE VIRTUAL REALITY TRAINING ON HAND MOTOR FUNCTION AMONG HEMIPARETICS

SATHYABAMA INSTITUTE OF SCIENCE AND TECHNOLOGY1 site in 1 country76 target enrollmentStarted: December 16, 2024Last updated:

Overview

Phase
Not Applicable
Status
Not yet recruiting
Sponsor
SATHYABAMA INSTITUTE OF SCIENCE AND TECHNOLOGY
Enrollment
76
Locations
1
Primary Endpoint
1.Post test – fugyl meyer assessment UE Hand component

Overview

Brief Summary

Virtual reality training is one of the advanced form of rehabilitation. Immersion into unrealistic environment provides various sensory feedback. The synapse VR application designed to improve hand motor function among hemiparetic patients. The activities are believed to facilitate the hand motor function.

Hemiparetic subjects will be recruited based upon inclusion and exclusion criteria and randomly allocated into two groups. Informed consent will be obtained. participants are assigned and evaluated for the outcome measures. Group A receives Immersive virtual reality intervention and group B receives conventional rehabilitation exercise program for 6 weeks and follow up measures were taken after 12 weeks.

Study Design

Study Type
Interventional
Allocation
Randomized
Masking
Investigator Blinded

Eligibility Criteria

Ages
45.00 Year(s) to 60.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • Acute to subacute stroke more than one month of onset to six months Hemiparetic subjects.
  • Ischemic 0r hemorrhage stroke Conscious and comprehensive MMSE – 24- 30 Educational level – Basic qualification.

Exclusion Criteria

  • Multiple infarcts or hemorrhage Cognitive impairment Vertigo Motion sickness Other neurological, visual, musculoskeletal conditions Sensory problems.

Outcomes

Primary Outcomes

1.Post test – fugyl meyer assessment UE Hand component

Time Frame: 1st measure - BASELINE | 2nd measure - AFTER 6 WEEKS | 3rd measure - after follow up of 12 weeks

2.Box and block test

Time Frame: 1st measure - BASELINE | 2nd measure - AFTER 6 WEEKS | 3rd measure - after follow up of 12 weeks

Secondary Outcomes

  • BDNF - BRAIN DERIVED NEUROTROPHIC FACTOR(8.0–927.0pg per ml)

Investigators

Sponsor
SATHYABAMA INSTITUTE OF SCIENCE AND TECHNOLOGY
Sponsor Class
Private hospital/clinic
Responsible Party
Principal Investigator
Principal Investigator

VISHNU PRIYA M

SATHYABAMA INSTITUTE OF SCIENCE AND TECHNOLOGY

Study Sites (1)

Loading locations...

Similar Trials